Wendy’s® franchisee’s Jr. Frosty® fundraiser benefits TGen cancer research Posted Monday April 4, 2022 Fundraising starts today at nearly 200 Wendy’s in 10 states, including more than 60 locations across Arizona
TGen-Temple review suggests even normal weight individuals are susceptible to severe fatty liver disease Posted Thursday March 24, 2022 Risk factors could include diet, genetics and ethnicity; no global consensus on how to screen for potentially deadly liver conditions
Could diet modification make chemotherapy drugs more effective for patients with pancreatic cancer? Posted Monday March 21, 2022 Laboratory experiments at Princeton University and TGen, testing a ketogenic diet, lead to nationwide clinical trial
TGen, HonorHealth and Irish biomedical team initiate promising ‘Nieto’ clinical trial against pancreatic cancer Posted Friday March 18, 2022 Named for a respected Arizona scientist, this trial uses a combination of drugs against advanced cancer in patients where other treatments have failed
‘Purple Pansies’ donates $1 million in support of TGen pre-clinical study Posted Wednesday February 23, 2022 Disrupting cancer cells’ ability to formulate proteins could open door to improved treatment of pancreatic cancer
TGen partners with Deepcell to advance detection, analysis and treatment of disease Posted Tuesday February 22, 2022 Technology platform provides state-of-the-art imaging and analysis of individual cells
Understudied lncRNAs could help enable early detection of potentially deadly liver disease Posted Tuesday February 8, 2022 TGen-Temple comprehensive review highlights recently discovered associations between long noncoding RNAs and specific diseases
TGen-led international team identifies genes associated with suicide Posted Monday January 10, 2022 Analysis of molecular-level biological changes could lead to better predictive models that would enhance assessment of suicide risk
TGen-UArizona medical school study points to possible new treatment options for breast cancer patients Posted Wednesday December 22, 2021 Cxcl10 protein can indicate both positive and negative directions of cancer trajectory
TGen helps develop analysis tool, leading to more-accurate evaluation of new brain tumor treatments and individual estimates of survival Posted Monday December 20, 2021 ‘Nomograms’ accounting for sex differences in the design of clinical trials should help deliver new precision treatments to glioblastoma patients